AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center
AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy - Drug Discovery and Development
AveXis nabs breakthrough tag for gene therapy, plans pivotal trial start in 2017 | Fierce Biotech
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
AveXis Receives FDA Breakthrough Therapy Designation for AVXS-101 (Gene Therapy) for SMA - Cure SMA
AveXis Knew of 'Manipulated' Data in Zolgensma Application, FDA Says
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
g925518.jpg
AveXis Presents Promising Trial Results of Gene Therapy for SMA Type 1
AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
25 Up-and-Coming Gene Therapies of 2019
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
g944461.jpg
Zolgensma® – TreatSMA
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
With new AveXis name, Novartis spotlights marquee role for gene therapy business | Fierce Pharma
AveXIS Announcement – Utah Program for Inherited Neuromuscular Disorders
Avexis — PBM Capital
Novartis-bound AveXis posts early look at data from pivotal SMA gene therapy trial | Fierce Biotech
AveXis Gene Therapy Manufacturing Facility, North Carolina, USA
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
Promising results in phase 1 SMA gene therapy trial - Muscular Dystrophy Association
AveXis Issues Community Statement on AVXS-101 Clinical Hold - Cure SMA
A 2nd Patient Death Reported in Novartis' Gene Therapy Trial | BioSpace
avxs_Current_Folio_10K
AveXis chooses BIA Separations to support gene therapy pipeline
The world's most expensive drug?
FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy
Another Zolgensma red flag, another delay in data reporting at Novartis' AveXis | Fierce Pharma
